Next Article in Journal
Degradation of Aflatoxin B1 and Zearalenone by Bacterial and Fungal Laccases in Presence of Structurally Defined Chemicals and Complex Natural Mediators
Previous Article in Journal
Contribution and Interaction of Shiga Toxin Genes to Escherichia coli O157:H7 Virulence
Previous Article in Special Issue
Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis
Open AccessArticle

Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine

1
Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
2
Unit of Neurorehabilitation, Department of Medical Specialties, University Hospital of Pisa, 56126 Pisa, Italy
*
Author to whom correspondence should be addressed.
Toxins 2019, 11(10), 608; https://doi.org/10.3390/toxins11100608
Received: 7 August 2019 / Revised: 30 September 2019 / Accepted: 16 October 2019 / Published: 19 October 2019
(This article belongs to the Special Issue Botulinum Toxin for Neuropathic Pain Treatment)
The pathophysiological mechanisms of migraine transformation are debated. Modifications of plasma oxidative stress biomarkers have been described in chronic migraine. OnabotulintoxinA (BoNT/A) treatment, approved for chronic migraine prophylaxis, possibly reduces pain neurotransmitters release and oxidative stress products. Aims of our study were to investigate differences in the levels of selected plasmatic oxidative stress biomarkers (Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), Thiolic Groups (SH)) comparing chronic migraineurs (CM) and healthy controls (HC). We also explored possible clinical and biochemical modifications in the CM group after six months of treatment with BoNT/A. At the baseline, we found higher values of AOPP (p < 0.001), and lower values of SH (p < 0.001) and FRAP (p = 0.005) in the CM group. At the six-month follow-up we found a reduction of AOPP (p < 0.001) and an increase of FRAP (p < 0.001) and SH (p = 0.023) within the CM group. BoNT/A treatment improved migraine symptoms in the CM group. We confirmed previous reports of imbalanced antioxidant mechanisms in chronic migraine showing lower antioxidant capacities in patients than controls. BoNT/A improved the levels of plasma oxidative stress biomarkers and confirmed its role as an effective prophylactic treatment for CM. Other studies should investigate the potential antioxidant properties of BoNT/A treatment. View Full-Text
Keywords: migraine; chronic migraine; medication overuse headache; BoNT/A; oxidative stress; biomarkers migraine; chronic migraine; medication overuse headache; BoNT/A; oxidative stress; biomarkers
MDPI and ACS Style

Dini, E.; Mazzucchi, S.; De Luca, C.; Cafalli, M.; Chico, L.; Lo Gerfo, A.; Siciliano, G.; Bonuccelli, U.; Baldacci, F.; Gori, S. Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine. Toxins 2019, 11, 608.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop